Sipai Health Technology Co (FRA:AX1) ROCE %: -9.64% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AX1 Sipai Health Technology Co Ltd FRA:AX1
64 GF Score
Price €0.14
GF Value €0.22
! 5 Warning Signs
View Full Analysis

What is Sipai Health Technology Co ROCE %?

Sipai Health Technology Co FRA:AX1 -2.80% 64 ROCE % is -9.64% as of Dec. 2025. GuruFocus rates FRA:AX1 with a GF Score™ of 64/100 and a GF Value™ of €0.22. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sipai Health Technology Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -9.64%.

Sipai Health Technology Co  (FRA:AX1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sipai Health Technology Co ROCE % Related Terms

Sipai Health Technology Co ROCE % Historical Data

* Premium members only.

The historical data trend for Sipai Health Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sipai Health Technology Co ROCE % Chart

Sipai Health Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -199.70 -68.39 -13.27 -24.95 -11.31

Sipai Health Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.81 -9.12 -41.41 -14.17 -9.64
FRA:AX1
64GF Score
Sipai Health Technology Co Ltd FRA:AX1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sipai Health Technology Co ROCE % Calculation

Sipai Health Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-15.366/( ( (297.135 - 135.971) + (194.355 - 83.695) )/ 2 )
=-15.366/( (161.164+110.66)/ 2 )
=-15.366/135.912
=-11.31 %

Sipai Health Technology Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-10.962/( ( (221.245 - 104.46) + (194.355 - 83.695) )/ 2 )
=-10.962/( ( 116.785 + 110.66 )/ 2 )
=-10.962/113.7225
=-9.64 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -9.64% mean?
Sipai Health Technology Co (FRA:AX1) has a ROCE % of -9.64% as of Dec. 2025.
Is Sipai Health Technology Co's ROCE % too high?
Sipai Health Technology Co's current ROCE % is -9.64%. Overall, Sipai Health Technology Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Sipai Health Technology Co's ROCE % compare to MCK and COR?
Sipai Health Technology Co's ROCE % of -9.64% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.95, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sipai Health Technology Co's current ROCE % is -9.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sipai Health Technology Co stock overvalued right now?
Sipai Health Technology Co (FRA:AX1) has a current ROCE % of -9.64%. The stock's GF Value™ is €0.22, compared to a current price of €0.14 — trading 36.8% below its estimated fair value. The current ROCE % is -9.64%. Sipai Health Technology Co's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sipai Health Technology Co (FRA:AX1), the current ROCE % is -9.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sipai Health Technology Co (FRA:AX1) Overvalued in 2026?

Based on GuruFocus' analysis, Sipai Health Technology Co stock appears to be undervalued. The current stock price of €0.14 is trading 36.8% below its estimated GF Value™ of €0.22.

Key valuation signals for FRA:AX1:

  • ROCE %: -9.64%
  • GF Value™: €0.22 vs. price of €0.14 (36.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the FRA:AX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sipai Health Technology Co Business Description

Other Exchanges 00314:Hong Kong
Address 128 Tianmu West Road, 1603-1605A, 16th Floor, Tower 1, Kerry Enterprise Center, Jing\'an District, Shanghai, CHN
Sipai Health Technology Co Ltd is a medical technology and health management company in China. The company has three reportable operating segments: Specialty Pharmacy Business - engaged in the operation and distribution of specialty pharmacy stores and pharmaceutical products; Physician Research Assistance Business - offering pharmaceutical companies and other clinical trial institutions site management organization services; Commercial Insurance Services Business - rendering insurance brokerage services to insurance companies and health management services to insurance carriers and enterprise clients. The company generates key revenue from the Specialty Pharmacy Business. Almost all of the company's revenues were derived from operations in the PRC.
64GF Score

Get the complete analysis for FRA:AX1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.22
GF Value